OM-RCA-01 |
|
Catalog No.GC81314
|
OM-RCA-01 is an anti- FGFR1 monoclonal antibody with a K d of 1.59 nM for human FGFR1.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
In Vivo, OM-RCA-01 (30 mg/kg; i.v.; twice weekly) induces a statistically significant two-fold reduction in median tumor volume and delays tumor growth in A549 lung cancer xenograft models, and combination with Pembrolizumab achieves 89% tumor growth inhibition[1]. OM-RCA-01 (30 mg/kg; once every 3 days) achieves 96% tumor growth delay in the cancer-associated fibroblast (CAF)-positive renal cell carcinoma cohort and 75% tumor growth delay in the CAF-negative renal cell carcinoma cohort, while increasing IFN-γ and IL-2 cytokine levels[1].
In Vitro, OM-RCA-01 binds to FGFR1 with high affinity (Kd = 1.59 nM) and inhibits its in vitro kinase activity[1]. OM-RCA-01 (1-100 μg/mL, 3 h) potently inhibits FGFR1 phosphorylation and cell proliferation in FGFR1-overexpressing human lung cancer cell line A549 (GI50 = 9.69 μg/mL), but exerts no significant effect on FGFR1-low-expressing human melanoma cell line Mel Kor[1]. OM-RCA-01 (0.5-10 nmol/L; 5 days) enhances Nivolumab-induced IFN-γ release and T-cell proliferation in a human allogeneic MLR assay, whereas it exhibits minimal effects when used alone when combined with Nivolumab [1]. OM-RCA-01 (1 μg/mL; 4 days) increases Nivolumab-induced IL-2 secretion by 29%-74% in human peripheral blood mononuclear cells (PBMCs) stimulated with Staphylococcal enterotoxin B (SEB) [1].
References:
[1]. Tsimafeyeu I, et al. A novel anti-FGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer models. Immunooncol Technol. 2024;23:100725. Published 2024 Jul 26.
| Cas No. | SDF | ||
| Formula | M.Wt | 144.85 | |
| Solubility | Storage | Store at -20°C | |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.9037 mL | 34.5185 mL | 69.0369 mL |
| 5 mM | 1.3807 mL | 6.9037 mL | 13.8074 mL |
| 10 mM | 690.4 μL | 3.4518 mL | 6.9037 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A liquid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)















